SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

S33 - Progressive MS Therapeutics

Event Time: Wednesday April 26, 2017 3:30 pm to 5:30 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
5:05 PM - 5:30 PM Discussion Daniel Ontaneda MD 

Disclosures

Speaker Disclosure
Daniel Ontaneda, MD Dr. Ontaneda has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Biogen Idec.

Abstract Presenters

Start Time Pub. Title Presenter
3:54 PM 003 Retinal Nerve Fiber Layer Thickness defines Multiple Sclerosis Patients at Risk of Future Disease Progression Pablo Villoslada
Disclosure:
Dr. Villoslada has received personal compensation for activities with Genzyme for participating in a scientific advisory board. Dr. Villoslada has received personal compensation in an editorial capacity for Current Treatment Options in Neurology. Dr. Villoslada holds stock and/or stock options in Bionure Inc. Dr. Villoslada has received research support from Biogen, Genzyme, Novartis and Merck Serono.

4:06 PM 004 Efficacy Results from the Phase 2b SYNERGY Study: Treatment of Disabling Multiple Sclerosis with the Anti-LINGO-1 Monoclonal Antibody Opicinumab Michelle Mellion, MD
Disclosure:
Compensation for consulting from Biogen, and Vertex. Research support from Annexon, Biogen, MedImmune, Novartis, Sanofi, and Teva.

4:18 PM 005 Development of a sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Peter Kosa, PhD
Disclosure:
Dr. Kosa has nothing to disclose.

4:30 PM 006 The Association Between Confirmed Disability Progression and Patient-Reported Fatigue in PPMS Patients in the ORATORIO study Deborah Miller, PhD
Disclosure:
Dr. Miller has received personal compensation in an editorial capacity for Quality of Life Research. Dr. Miller has received research support from Novartis.

4:42 PM 007 Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis: Robert Fox, MD, FAAN
Disclosure:
Consultant fees from Actelion, Biogen, Genentech, Mallinckrodt, MedDay, Novartis, and Teva... Research support from Biogen (clinical trial contracts) and Novartis (research study support).

4:54 PM 008 Long-term Outcomes in Patients with Progressive MS with Relapses: Analysis of TEMSO and TOWER Extension Data Flavia Nelson
Disclosure:
Dr. Nelson has received personal compensation for activities with Bayer, Sanofi-Genzyme, Genentech, Novartis, Teva, and CMSC. Dr. Nelson has received research support from National Institutes of Health, National MS Society, and Novartis.

Register Now

Related Courses

Saturday April 21, 2018

9:30 AM-11:30 AM
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
3:30 PM-5:30 PM
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Tuesday April 24, 2018

7:00 AM-9:00 AM
C98 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
1:00 PM-3:00 PM
C108 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
3:30 PM-5:30 PM
C122 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C136 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C147 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
3:30 PM-5:30 PM
C162 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD

Thursday April 26, 2018

7:00 AM-9:00 AM
C175 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN

Friday April 27, 2018

1:00 PM-3:00 PM
C224 Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN

MEMBER LOG IN

Forgot Password?